NEOSTAR Results Indicate that Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses in Operable NSCLC
Phase II randomised study met prespecified primary endpoint threshold in patients with operable non-small cell lung cancer
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
EMA Recommends Granting a Marketing Authorisation for Generic Abiraterone for the Treatment of Metastatic Prostate Cancer
Abiraterone Accord is a generic of Zytiga, which has been authorised in the EU since 2011
Significant Benefits of Nivolumab Plus Cabozantinib Over Sunitinib in Previously Untreated Advanced RCC
Results of CheckMate 9ER study in patients with previously untreated advanced clear cell renal-cell carcinoma
EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab
Combination of cabozantinib and nivolumab is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma
Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in Patients With Refractory and Relapsed Multiple Myeloma
Substantial antitumour activity observed with idecabtagene vicleucel in the KarMMa study
Poziotinib Shows Promise in EGFR and HER2 Exon 20 Mutated Non-Small Cell Lung Cancer
Twice daily poziotinib dosing improved the adverse event profile; early results showed retained anti-tumour activity
Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with FGFR Amplifications
Clinical benefit of FGFR inhibition is stronger in patients with an FGFR fusion or mutation compared to FGFR amplification
Tumour Signatures Defined by Next Generation Sequencing Are Linked to Clinical Response in Breast Cancer
Endogenous and exogenous mutational processes driven by abnormal DNA editing, mutagens or age-related DNA alterations over the history of a malignant tumour provide an individual tumour signature
Encouraging Early Results Seen with Novel MEDI1191 in Advanced Tumours
Prelliminary data with IL-12 mRNA administered by intratumoural injection in combination with intravenous durvalumab
Characterisation of Toxicity Profiles of Immune and Molecularly Targeted Agents in Phase I and II Studies
Overall, more adverse events were reported with targeted therapies than with immunotherapy.
The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not Be Elevated in Patients with Autoimmune Disease
Many cancer patients with autoimmune disease are excluded from studies of immune checkpoint inhibitors due to hypothesis of the association of this treatment with immune-related adverse events
EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab
It is intended for the treatment of recurrent or advanced dMMR/MSI-H endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen